Pulmonary coccidioidomycosis
ICD-10 B39.5 is a billable code used to indicate a diagnosis of pulmonary coccidioidomycosis.
Pulmonary coccidioidomycosis is a fungal infection caused by the inhalation of spores from the Coccidioides species, primarily C. immitis and C. posadasii. This condition is endemic to certain regions, particularly the southwestern United States, parts of Mexico, and Central and South America. The infection can manifest as a mild respiratory illness or progress to more severe forms, including pneumonia, which may lead to chronic pulmonary disease or disseminated coccidioidomycosis in immunocompromised individuals. Symptoms often include cough, fever, chest pain, and fatigue. Diagnosis is typically confirmed through serological tests, culture, or histopathological examination. Treatment options include antifungal medications such as fluconazole or itraconazole, particularly for patients with severe or disseminated disease. Immunocompromised patients, including those with HIV/AIDS, cancer, or those on immunosuppressive therapy, are at a higher risk for severe manifestations of the disease and may require more aggressive treatment and monitoring.
Detailed patient history, including travel history and exposure risks, laboratory results, and treatment response.
Patients presenting with respiratory symptoms after travel to endemic areas, or those with chronic cough and fever.
Consideration of co-morbid conditions and potential for disseminated disease in immunocompromised patients.
Pulmonary function tests, imaging studies, and treatment plans.
Patients with chronic cough, hemoptysis, or pneumonia-like symptoms.
Monitoring for potential complications such as lung abscesses or cavitary lesions.
Used to confirm diagnosis in patients presenting with respiratory symptoms.
Document the reason for testing and results.
Infectious disease specialists may order this test more frequently.
Common symptoms include cough, fever, chest pain, and fatigue. Some patients may experience more severe respiratory distress.
Diagnosis is typically made through serological tests, imaging studies, and clinical evaluation of symptoms.
Treatment usually involves antifungal medications such as fluconazole or itraconazole, especially in cases of severe or disseminated disease.
